Compare XBIT & BSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XBIT | BSL |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | United States | United States |
| Employees | 87 | N/A |
| Industry | Pharmaceuticals and Biotechnology | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.8M | 168.7M |
| IPO Year | 2015 | 2010 |
| Metric | XBIT | BSL |
|---|---|---|
| Price | $2.17 | $13.05 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 43.1K | ★ 55.9K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.55% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.09 | $12.45 |
| 52 Week High | $3.44 | $14.19 |
| Indicator | XBIT | BSL |
|---|---|---|
| Relative Strength Index (RSI) | 42.52 | 53.75 |
| Support Level | N/A | $12.87 |
| Resistance Level | $2.46 | $13.04 |
| Average True Range (ATR) | 0.05 | 0.06 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 23.53 | 57.50 |
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
Blackstone Senior Floating Rate Term Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. The fund also invests in second-lien loans and high yield bonds and employs financial leverage which may increase the risk to the Fund.